vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
19.67
-0.03 (-0.15%)
Apr 21, 2025, 4:00 PM EDT - Market closed
vTv Therapeutics Employees
vTv Therapeutics had 23 employees as of December 31, 2024. The number of employees increased by 7 or 43.75% compared to the previous year.
Employees
23
Change (1Y)
7
Growth (1Y)
43.75%
Revenue / Employee
$44,217
Profits / Employee
-$802,696
Market Cap
62.74M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
VTVT News
- 4 weeks ago - vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges - Benzinga
- 5 weeks ago - vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes - GlobeNewsWire
- 4 months ago - CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER - PRNewsWire
- 5 months ago - vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewsWire
- 9 months ago - vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold - GlobeNewsWire
- 10 months ago - vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes - GlobeNewsWire